deepc Partners with PAIRE to Innovate Nuclear Medicine
deepc is pleased to announce a strategic partnership with PAIRE, a leading AI solutions provider for PET/CT examinations. This collaboration will integrate PAIRE’s whole-body AI solution, Pionus, into the deepcOS platform, enhancing the precision and efficiency of PET/CT scan interpretations.
PAIRE’s Pionus on deepcOS:
A first of its kind, this innovative AI solution automatically detects, segments, and quantifies every hypermetabolic foci in FDG PET/CT examinations, highlighting anomalies with clear contours and providing standard quantifications used in nuclear medicine reports. Pionus serves as a safeguard to avoid errors, increases efficiency, and computes essential biomarkers for metabolic activity in clinical routines including Total Metabolic Tumor Volume (TMTV) and Total Lesion Glycolysis (TLG).
Key benefits include
- Error Prevention: Acts as a safeguard with 90% sensitivity and 85% agreement with medical reports.
- Increased Efficiency: Streamlines the workflow by computing biomarkers in clinical routine.
- Comprehensive Coverage: Suitable for any whole-body PET/CT FDG exam.
By leveraging AI for PET/CT FDG exams, deepc and PAIRE are at the forefront of transforming nuclear medicine diagnostics. The integration of Pionus into deepcOS exemplifies our dedication to enhancing the precision and efficiency of nuclear imaging. This collaboration provides nuclear medicine physicians with powerful AI tools that seamlessly fit into their existing systems, enabling more accurate detection and quantification of hypermetabolic foci. Through such advancements, deepc aims to support the global medical community in delivering superior patient care and advancing the future of nuclear medicine.
